ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5

In Sino Biopharmaceutical’s pipeline, 41BBcondi/CEACAM5双抗. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 2, since Dec 4, 20232 company-led studies, 2 open or runningNext primary completion: May 21, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical22 open or runningphase 2since Dec 4, 2023Dec 4, 2023May 21, 2028phase 2 · NCT07387081
  • Named in Sino Biopharmaceutical’s own pipeline as LM-24C5, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2023First study: phase 2 study in Advanced Solid TumorFirst studyNCT06187402 · 49 planned · United States
  2. Dec 2, 2025Phase 2 study in Advanced Solid Tumor CancerNCT07387081 · 130 planned · China

Ahead

  1. May 21, 2028Primary completion: phase 2 study in Advanced Solid Tumor CancerNCT07387081

TargetBeta

“41BBcondi/CEACAM5双抗”the company's pipeline, read by Claude · source
“A bispecific antibody targeting both the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07387081Advanced Solid Tumor Cancer · China2RecruitingMay 21, 2028130
NCT06187402Advanced Solid Tumor · United States2RecruitingJun 30, 202649

How it is read

Names in the registry

  • “LM-24C5”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.